How common is Prostate cancer?

['Henoy ity pejy ity']

Inona no mahafeno fepetra?

Ny homamiadan'ny prostate no karazana homamiadana mahazatra indrindra amin'ny lehilahy, indrindra amin'ny lehilahy antitra.

Araka ny Fikambanana Amerikanina momba ny homamiadana, ny homamiadan'ny prostate no homamiadana faharoa mahazatra indrindra amin'ny lehilahy Amerikana, aorian'ny homamiadan'ny hoditra.

Any Etazonia, eo amin'ny lehilahy 1 amin'ny 9 eo no ho voan'ny homamiadan'ny prostate mandritra ny androm-piainany.

Amin'ny 2021, vinavinaina ho 248.530 ireo tranga vaovao momba ny homamiadan'ny prostate ary 34.130 ireo fahafatesana noho ny homamiadan'ny prostate.

Tsara homarihina anefa fa mora tsaboina ny kanseran'ny prostate, ary tena mora sitrana ny olona voan'izy io raha hita aloha.

['Fanamarihana']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Fesinmeyer MD, Gulati R, Zeliadt S, Weiss N, Kristal AR, Etzioni R: Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States. Cancer Epidemiol Biomarkers Prev. 2009, 18 (3): 808-15.

Peng P, Gong YM, Bao PP, Ke JZ, Xiang YM, Zhang ML, Zheng Y: [Estimates and prediction of prostate cancer incidence, mortality and prevalence in China, 2008]. Zhonghua Liu Xing Bing Xue Za Zhi. 2012, 33 (10): 1056-9.

Delongchamps NB, Singh A, Haas GP: The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006, 13 (3): 158-68.

Li J, German R, King J, Joseph D, Thompson T, Wu XC, Ajani U, Tai E: Recent trends in prostate cancer testing and incidence among men under age of 50. Cancer Epidemiol. 2012, 36 (2): 122-7.

Yu XQ, Luo Q, Smith DP, Clements MS, O'Connell DL: Prostate cancer prevalence in New South Wales Australia: a population-based study. Cancer Epidemiol. 2015, 39 (1): 29-36.

Ondrusova M, Mrozova L, Ondrus D, Mrinakova B: Trends and estimates in prostate cancer incidence, mortality and prevalence in the Slovak Republic, 1968-2012. Neoplasma. 2013, 60 (4): 446-51.

['Fialana andraikitra: fitsaboana']

['Natao hampianarana sy hampahafantarana fotsiny ity tranonkala ity, fa tsy natao hanomezana torohevitra ara-pitsaboana na tolotra matihanina.']

['Tsy tokony hampiasaina mba hamantarana na hitsaboana olana ara-pahasalamana na aretina ny fanazavana omena, ary tokony hanatona dokotera manana fahazoan-dalana hitsabo tena ireo mitady torohevitra ara-pitsaboana.']

["Mariho tsara fa ny tambajotra neural izay mamorona ny valin'ny fanontaniana, dia tsy marina indrindra raha resaka isa no resahina. Ohatra, ny isan'ny olona voamarina fa voan'ny aretina manokana."]

["Mitadiava torohevitra avy amin'ny dokotera na mpitsabo hafa mahay momba ny toe-pahasalamanao. Aza atao tsinontsinona mihitsy ny torohevitra ara-pitsaboana matihanina na manemotra ny fikatsahana azy noho ny zavatra novakianao tao amin'ity tranonkala ity. Raha mieritreritra ianao fa mety manana vonjy taitra ara-pitsaboana, antsoy ny 911 na mandehana any amin'ny efitrano fitsaboana maika akaiky indrindra avy hatrany. Tsy misy fifandraisana mpitsabo-marary noforonin'ity tranonkala ity na ny fampiasana azy. Na ny BioMedLib na ny mpiasa ao aminy, na ny mpandray anjara amin'ity tranonkala ity, dia tsy manao fanambarana, mazava na tsy mazava, momba ny fampahalalana omena eto na ny fampiasana azy."]

["Fanamarihana: zon'ny mpamorona"]

["Ny Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (ny DMCA) dia manome vahaolana ho an'ireo tompon'ny zon'ny mpamorona izay mino fa manitsakitsaka ny zony araka ny lalàna momba ny zon'ny mpamorona ao Etazonia ny fitaovana hita ao amin'ny Internet. "]

["Raha mino ianao fa misy votoaty na fitaovana azo ampiasaina amin'ny tranonkalanay na ny tolotra ataonay manitsakitsaka ny zon'ny mpamorona anao, dia afaka mandefa filazana aminay ianao (na ny mpandraharaha anao) mangataka ny hanesorana ny votoaty na ny fitaovana, na ny fanakanana ny fidirana amin'izany. "]

['Tsy maintsy alefa an-tsoratra amin\'ny alalan\'ny mailaka ny filazana (jereo ny fizarana "Contact" raha mila adiresy mailaka). ']

["Ny DMCA dia mitaky ny fampandrenesanao ny voalaza ho fanitsakitsahana ny zon'ny mpamorona ahitana ireto fampahalalana manaraka ireto: (1) famaritana ny asa voaaro zon'ny mpamorona izay voalaza fa voahitsakitsaka; (2) famaritana ny votoaty voalaza fa manitsakitsaka sy fampahalalana ampy ahafahantsika mahita ny votoatiny; (3) fampahalalana momba anao, anisan'izany ny adiresinao, nomeraon-telefaona ary adiresy mailaka; (4) fanambarana avy aminao fa mino tsara ianao fa ny votoaty amin'ny fomba nitarainana dia tsy nomen'ny tompon'ny zon'ny mpamorona alalana, na ny mpandraharahany, na amin'ny asan'ny lalàna rehetra; "]

["(5) fanambarana nosoniavinao, eo ambany sazin'ny fianianana diso, fa marina ny vaovao ao amin'ny fampahafantarana ary manana fahefana hampihatra ny zon'ny mpamorona izay voalaza fa voahitsakitsaka ianao; "]

["ary (6) sonia ara-batana na elektronika avy amin'ny tompon'ny zon'ny mpamorona na olona nahazo alalana hiasa amin'ny anaran'ny tompon'ny zon'ny mpamorona. "]

["Mety hiteraka fahatarana amin'ny fikarakarana ny fitarainanao ny tsy fampidirana ireo vaovao rehetra voalaza etsy ambony."]

['Fifandraisana']

['Alefaso mailaka izahay raha misy fanontaniana / sosokevitra.']

How common is prostate cancer?

Prostate cancer is one of the most common types of cancer in men, particularly in older men.

According to the American Cancer Society, prostate cancer is the second most common cancer in American men, behind skin cancer.

In the United States, about 1 in 9 men will be diagnosed with prostate cancer during their lifetime.

In 2021, it is estimated that there will be about 248,530 new cases of prostate cancer and about 34,130 deaths from prostate cancer.

However, it is important to note that prostate cancer is highly treatable, and the survival rate is high when it is detected early.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.